Literature DB >> 8096505

Cellular models for multiple drug resistance in cancer.

M Clynes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8096505     DOI： 10.1007/bf02634176

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN： 0883-8364


× No keyword cloud information.
  150 in total

1.  Analysis of the mechanism of resistance of 7 novel MDR variants.

Authors:  A Redmond; E Moran; M Clynes
Journal:  Biochem Soc Trans       Date:  1992-02       Impact factor: 5.407

2.  Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes.

Authors:  A D Lewis; D H Lau; G E Durán; C R Wolf; B I Sikic
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

Review 3.  The clinical relevance of multidrug resistance.

Authors:  W T Bellamy; W S Dalton; R T Dorr
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

4.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.

Authors:  J M Croop; M Raymond; D Haber; A Devault; R J Arceci; P Gros; D E Housman
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

5.  Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.

Authors:  P Gros; J Croop; D Housman
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

6.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

7.  Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies.

Authors:  E Georges; G Bradley; J Gariepy; V Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

8.  Amplicon structure in multidrug-resistant murine cells: a nonrearranged region of genomic DNA corresponding to large circular DNA.

Authors:  F Ståhl; Y Wettergren; G Levan
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.

Authors:  E B Mechetner; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

10.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701
View more
  6 in total

Review 1.  Multiple drug resistance and intermediate filaments.

Authors:  A E Cress; W S Dalton
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

2.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

6.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.